Reata Pharmaceuticals, Inc. is a pharmaceutical company based in

Plano, Texas Plano ( ) is a city in Collin County and Denton County, Texas, United States. It had a population of 285,494 at the 2020 census. It is a principal city of the Dallas–Fort Worth metroplex. History European settlers came to the area near ...

. Founded in 2002, Reata is primarily focused on investigating experimental oral antioxidative and

anti-inflammatory Anti-inflammatory is the property of a substance or treatment that reduces inflammation or swelling. Anti-inflammatory drugs, also called anti-inflammatories, make up about half of analgesics. These drugs remedy pain by reducing inflammation as o ...

drugs, which dually activate the antioxidative transcription factor

Nrf2 Nuclear factor erythroid 2-related factor 2 (NRF2), also known as nuclear factor erythroid-derived 2-like 2, is a transcription factor that in humans is encoded by the ''NFE2L2'' gene. NRF2 is a basic leucine zipper (bZIP) protein that may reg ...

and inhibit the pro-inflammatory transcription factor

NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a protein complex that controls transcription of DNA, cytokine production and cell survival. NF-κB is found in almost all animal cell types and is involved in cellular ...

Pipeline

The antioxidative and anti-inflammatory compounds

bardoxolone methyl Bardoxolone methyl (also known as “RTA 402”, “CDDO-methyl ester”, CDDO-Me, and more formally methyl bardoxolonate) is an experimental and orally-bioavailable semi-synthetic triterpenoid, based on the scaffold of the natural product olean ...

and RTA 408 are the lead clinical development compounds in Reata’s portfolio.

Bardoxolone Methyl

Bardoxolone methyl Bardoxolone methyl (also known as “RTA 402”, “CDDO-methyl ester”, CDDO-Me, and more formally methyl bardoxolonate) is an experimental and orally-bioavailable semi-synthetic triterpenoid, based on the scaffold of the natural product olean ...

was one of the first of the class of synthetic triterpenoids to be studied in the clinic. It has been evaluated in Phase 1 studies for

cancer Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal b ...

, Phase 2 and 3 studies for chronic kidney disease (CKD) associated with

type 2 diabetes Type 2 diabetes, formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urinatio ...

, and is currently being evaluated in a Phase 2 study for pulmonary arterial hypertension.

RTA 408

Omaveloxolone (RTA 408) is a second generation member of the synthetic oleanane triterpenoid compounds and currently in clinical development. Preclinical studies have demonstrated that RTA 408 possesses antioxidative and anti-inflammatory activities, as well as the potential to improve mitochondrial bioenergetics. Because of the broad applicability of such effects across many diseases, RTA 408 is currently under clinical investigation in several Phase 2 clinical studies including

immunooncology Cancer immunotherapy (sometimes called immuno-oncology) is the stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer ...

, corneal endothelial cell loss associated with cataract surgery Friedreich’s ataxia, and

mitochondrial myopathies Mitochondrial myopathies are types of myopathies associated with mitochondrial disease. On biopsy, the muscle tissue of patients with these diseases usually demonstrate "ragged red" muscle fibers. These ragged-red fibers contain mild accumulation ...

Others

Reata is also actively engaged in the discovery of small molecule disease-modifying drugs that function by stabilizing the normal three-dimensional structure of target proteins or generally enhancing the folding environment of the cell. Defects in protein folding underlie a large number of genetic diseases including certain forms of

, familial Alzheimer's disease, and cystic fibrosis.

Protein folding Protein folding is the physical process by which a protein chain is translated to its native three-dimensional structure, typically a "folded" conformation by which the protein becomes biologically functional. Via an expeditious and reproduc ...

defects are also believed to play important roles in the development of non-inherited forms of many of these diseases.

Partnerships

Reata has a

licensing agreement A license (or licence) is an official permission or permit to do, use, or own something (as well as the document of that permission or permit). A license is granted by a party (licensor) to another party (licensee) as an element of an agreeme ...

with

Kyowa Hakko Kirin is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. History On ...

for development and commercialization of

for CKD and related indications in Japan, China,

Taiwan Taiwan, officially the Republic of China (ROC), is a country in East Asia, at the junction of the East and South China Seas in the northwestern Pacific Ocean, with the People's Republic of China (PRC) to the northwest, Japan to the nort ...

Korea Korea ( ko, 한국, or , ) is a peninsular region in East Asia. Since 1945, it has been divided at or near the 38th parallel, with North Korea (Democratic People's Republic of Korea) comprising its northern half and South Korea (Republic o ...

, and other select Southeast Asian countries. Reata also has a licensing agreement with

Abbvie AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. History On October 19, 2011, Abbott Laboratories announced its plan to separate into two publicly traded compani ...

for development and commercialization of bardoxolone methyl outside the U.S., excluding Asian markets defined in the agreement with

and Reata also have a second agreement for development of the second generation portfolio of synthetic oleanane triterpenoid compounds, including RTA 408, as well as other Nrf2 activators.

References

External links

* {{authority control Pharmaceutical companies of the United States Pharmaceutical companies established in 2002 Companies based in Plano, Texas Health care companies based in Texas Companies listed on the Nasdaq 2016 initial public offerings